Tirzepatide – 10mg
Research-grade Tirzepatide, a synthetic dual GLP-1/GIP receptor agonist peptide studied for metabolic and glucose homeostasis research. 10mg lyophilized powder, 99%+ purity verified by Janoshik Analytical via HPLC and mass spectrometry. CAS 2023788-19-2.
For laboratory research use only.
Not for human or veterinary use.
Not intended for diagnosis, treatment, cure, or prevention of any disease.
Use only in controlled laboratory settings by qualified personnel following appropriate safety procedures..
Tirzepatide is the compound behind well-known pharmaceutical brands in the dual-agonist space and has been widely discussed in metabolic research communities. It is frequently compared with Semaglutide in research settings exploring GLP-1 agonist efficacy differences. For those researching next-generation multi-agonists, Durham Peptides also carries Retatrutide, a triple agonist.
BENEFITS
Dual receptor activation — studied for simultaneous GIP and GLP-1 receptor engagement
Metabolic research — explored for body weight and composition changes in clinical trials
Glycemic control — linked to improvements in glucose homeostasis models
Comparative studies — frequently assessed alongside semaglutide in head-to-head research
Incretin biology — investigated for advancing understanding of dual-agonist pharmacology
WHAT RESEARCHERS LOOK AT
Dual GIP/GLP-1 receptor binding and activation profiles
Comparative efficacy vs mono-agonists (semaglutide, liraglutide)
Dose-dependent metabolic and body composition effects
Insulin sensitivity and beta-cell function modeling
Pharmacokinetic profiling and half-life analysis